@lastwalsh @KyleWalkerM @RheumNow Second question: do you ever give a PEXIVAS-standard style steroid taper? I'm 100% in agreement that we should favor PEXIVAS over observational data in most cases In practice it seems like some patients need a bit more immunosuppression, though Curious to hear your thoughts!

#Infection rates are equal in #RWD #real #world #data using #biosimilars compared to previous use of #originators. BC database #0970 #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ #arthritisresearchcanada #ARC https://t.co/eVSPgVfmQG

#ACR23 Abs #2199 large RL study: SEC retention rates after 4 yrs approx. 50% in axSpA and PsA pts. Bio-naïve pts had higher retention, remission & response rates than pts with prior b/tsDMARD exposure, particularly in axSpA. https://t.co/Eq5BwILK3D @rheumnow https://t.co/slho6yAwtQ

SPARTAN referral recommendations for axSpA #ACR23 Abs #2214 https://t.co/VQedpNynpv support Abs #2207 https://t.co/8RB0D4ef7i findings discussing that non-rheums are less aware of IBP components/asking about them in CBP pts. @rheumnow https://t.co/23oUONsMfb

The presence of antibodies to 4 UH-axSpA peptides was confirmed in the Belgian Inflammatory Arthritis and Spondylitis (Be-Giant) cohort of newly diagnosed axSpA patients and could be of added value for axSpA diagnosis. #ACR23 Abs #2210 https://t.co/fV4PPbWF01 @rheumnow

1-PJP prophylaxis or not in ANCA? 2-MTX single dose or split dose? 3-IL6 blocker early on in GCA/PMR? 4-SGLT2 in DM/Lupus nephritis? 5-Cervical cancer screening in Lupus? 6-TNF induced ILD? https://t.co/mzGXajmQqE @RheumNow , Daily recap #ACR23

PtGA and PhGA were aligned in most encounters in PsA. PtGA >PhGA disagreement was driven by pain, fatigue, and physical health being weighed more by Pts than Phs. PROs matter! #ACR23 Abs #2234 https://t.co/0r7gjx0JS6 @rheumnow https://t.co/BuGDicwBiB